Amsterdam, The Netherlands – 30 April 2019
Esperite N.V. announced on 22 February 2019 that the Company had signed an exclusive agreement regarding the potential acquisition (the Proposed Acquisition) of Cryo Save’s family stem cell banking business by PBKM (Famicord Group).
The Proposed Acquisition is a key milestone with regard to the future and strategy of the Company and is subject to the outcome of a due diligence process which is a complex operation. As a consequence additional time is needed to publish the Annual Report 2018.
Esperite continues to strive to publish its Annual Report 2018 and Half Year Results 2018 as promptly as practicable.
About ESPERITE
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.
***
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
Attachment
